60 Degrees Pharmaceuticals, Inc.
SXTP
$2.39
$0.135.75%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 168.65% | 128.90% | 12.09% | 2.63% | -50.39% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 168.65% | 128.90% | 12.09% | 2.63% | -50.39% |
| Cost of Revenue | 441.63% | 241.06% | 242.59% | -12.92% | -30.38% |
| Gross Profit | -608.93% | -261.93% | -376.49% | 21.98% | 7.45% |
| SG&A Expenses | 18.46% | 78.62% | 165.61% | 138.55% | 225.37% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 92.24% | 141.04% | 209.27% | 103.50% | 139.11% |
| Operating Income | -88.47% | -141.65% | -238.70% | -118.16% | -194.49% |
| Income Before Tax | -108.61% | -131.35% | 82.14% | 89.98% | 38.26% |
| Income Tax Expenses | -25.00% | -- | 250.00% | 0.00% | -33.33% |
| Earnings from Continuing Operations | -108.60% | -131.37% | 82.13% | 89.98% | 38.27% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -82.12% | 338.64% | 1,969.57% | 3,418.75% | 1,333.33% |
| Net Income | -111.03% | -130.84% | 82.65% | 90.66% | 39.08% |
| EBIT | -88.47% | -141.65% | -238.70% | -118.16% | -194.49% |
| EBITDA | -89.34% | -143.54% | -242.76% | -119.75% | -197.14% |
| EPS Basic | 79.56% | 69.07% | 101.86% | 70.77% | 3.82% |
| Normalized Basic EPS | 83.52% | 75.63% | 71.56% | 52.01% | -9.23% |
| EPS Diluted | 79.56% | 69.07% | 101.86% | 70.77% | 3.82% |
| Normalized Diluted EPS | 83.52% | 75.63% | 71.56% | 52.01% | -9.23% |
| Average Basic Shares Outstanding | 586.36% | 361.57% | 254.25% | 151.21% | 122.73% |
| Average Diluted Shares Outstanding | 586.36% | 361.57% | 254.25% | 151.21% | -98.61% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |